|
市場調查報告書
慢性阻塞性肺病（COPD）:市場與相關產品相關預測─儘管尚未開發的市場潛力成長的預測
Market and Product Forecasts: COPD - Growth expected despite untapped market potential
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229454 |
| 內容資訊 |
英文 Pages: 77 |
| 價格 |
|
|
慢性阻塞性肺病（COPD）:市場與相關產品相關預測─儘管尚未開發的市場潛力成長的預測 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 77 價格從美金11400起跳。
本報告提供2020年市場價值達到96億美元的慢性阻塞性肺病（COPD）治療藥物調查分析，預計將在未來10年銷售的14種新藥與預計的市場變化等資料彙整，為您概述為以下內容。
目錄
第1章 摘要整理
第2章 概況
第3章 市場定義
- 慢性阻塞性肺病相關市場定義
- 預測與採用的手法假設
- 預測的其他手法
第4章 市場概況及背景
- 現在及未來市場動態的概況
- 到2020年為止成為主流的支氣管擴張藥物聯合治療
- 學名藥進入以及新產品的銷售也促進市場成長
- 開發中產品和領導品牌的競爭的市場細分化
- 預測穩定成長的美國市場
- 大體上未開發的日本市場
- 10年來維持穩定成長的歐盟市場
- 法國
- 德國
- 義大利
- 西班牙
- 英國
第5章 各品牌相關預測
第6章 參考文獻
第7章 附錄
Description
Introduction
New product launches for COPD across the seven major markets will override generic erosion and boost market value from $8.2bn in 2011 to $9.6bn by 2020, representing a positive 2011-20 CAGR of 1.8%. Datamonitor forecasts 14 new product launches in COPD over the next 10 years, altering class dynamics and fracturing a market currently dominated by a handful of therapies.
Features and benefits
- Access Datamonitor's patient-based COPD market forecast for the seven major markets, with transparent methodology and clear assumptions.
- See how each new product launch will impact the market, and where the strongest competition lies.
- Gain insight into COPD market dynamics, and see where untapped market potential remains.
- Understand how currently marketed products are vulnerable to competition in the COPD market, and which products are insulated against brand erosion.
Highlights
- Datamonitor forecasts that sales for COPD will reach $8.2bn in 2011 in the seven major markets, growing to $9.6bn by 2020, representing a positive 2011-2020 CAGR of 1.8%, large untapped potential remains. Datamonitor's survey of 125 pulmonologists shows a low diagnosis rate and large untreated population, particularly among mild patients.
- Datamonitor estimates that in 2011 LAMAs dominate the COPD market with 27.1% market share, owing to the wide use of Spiriva. By 2020 highly anticipated LABA/LAMAs are forecast to hold 26.2% of the market, with sales of $2.5bn. The LAMA class's share will drop to 25.9%, with the class remaining popular among mild and moderate patients.
- Datamonitor estimates that in 2011 Spiriva and Advair together hold 64.4% of the COPD market. Generic erosion and 14 new product launches will result in a more fractured COPD market over the next 10 years. By 2020 Spiriva is forecast to remain the market leader, but its share will drop from 37% to 19%.
Your key questions answered
- What impact will generic erosion of key brands have on the launch of novel pipeline products?
- How will current market leaders be impacted by additional product launches and which products will resist brand erosion?
- How are class dynamics changing in COPD and what will be the most important drug class in 2020?
- How do dynamics in each of the seven major markets compare to each other and which factors have led to commercial success?
- Where does untapped patient potential remain?
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
MARKET DEFINITION
- Market definition for COPD
- Forecast methodology and assumptions
- Methodology flow
- Patent expiries
- New product launches
- Additional forecast methodology
MARKET OVERVIEW AND CONTEXT
- Current and future market dynamics overview
- Bronchodilator combinations to become a dominant class by 2020
- New product launches to drive growth despite generic entry
- Market to fracture as pipeline products compete with key brands
- Strong growth forecast for the US market
- The Japanese market is largely untapped
- The EU will see steady growth over the next 10 years
- France
- Germany
- Italy
- Spain
UK
BRAND FORECASTS
- Advair (fluticasone/salmeterol; GlaxoSmithKline)
- Forecast assumptions
- Advair forecast 2011-20
- Spiriva (tiotropium; Boehringer Ingelheim)
- Forecast assumptions
- Spiriva forecast 2011-20
- Symbicort (budesonide/formoterol; AstraZeneca)
- Forecast assumptions
- Symbicort forecast 2011-20
- Daliresp (roflumilast, Nycomed)
- Forecast assumptions
- Daliresp forecast 2011-20
- Arcapta Neohaler (QAB149, indacaterol; Novartis)
- Forecast assumptions
- Arcapta Neohaler forecast 2011-20
- Dulera (mometasone/formoterol; Merck & Co.)
- Forecast assumptions
- Dulera forecast 2011-20
- Eklira (aclidinium; Almirall)
- Forecast assumptions
- Eklira forecast 2011-20
- Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline)
- Forecast assumptions
- Relovair forecast 2011-20
- GSK573719/vilanterol (GlaxoSmithKline/Theravance)
- Forecast assumptions
- GSK573719/vilanterol forecast 2011-20
- QVA149 (indacaterol/glycopyrronium bromide; Novartis)
- Forecast assumptions
- QVA149 forecast 2011-20
- QMF149 (mometasone/indacaterol; Novartis)
- Forecast assumptions
- QMF149 forecast 2011-20
- PT003 (formoterol/glycopyrrolate; Pearl Therapeutics)
- Forecast assumptions
- PT003 forecast 2011-20
- Seebri Breezhaler (glycopyrronium bromide; Sosei/Novartis)
- Forecast assumptions
- Seebri Breezhaler forecast 2011-20
- Vilanterol (GlaxoSmithKline)
- Forecast assumptions
- Vilanterol forecast 2011-20
- GSK573719 (GlaxoSmithKline)
- Forecast assumptions
- GSK573719 forecast 2011-20
- Olodaterol/tiotropium (Boehringer Ingelheim)
- Forecast assumptions
- Olodaterol/tiotropium forecast 2011-20
- LAS40464 (aclidinium/formoterol; Almirall/Forest)
- Forecast assumptions
- LAS40464 forecast 2011-20
BIBLIOGRAPHY
- Websites
- Datamonitor reports
APPENDIX
- Contributing experts
- Forecast methodology
- Volume and value forecast methodology
- Price and compliance assumptions
- Physician sample breakdown
- Report methodology
|
